Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Treatments

Topic: Brain proteins, microglia and lab models

Plain-language summary

Results Among 16 enrolled participants, the mean (SD) age was 32.6 (4.4) years; 9 participants were women, and 7 were men. There were no cases of meningoencephalitis, death, or other serious adverse events (AEs) and no withdrawals as a result of AEs. Increases in anti-Aβ immunoglobulin G titers were observed in 4 of 12 participants (33.3%) receiving ACI-24 (2 receiving 300 μg and 2 receiving 1000 μg) compared with 0 participants receiving placebo. Evidence of immunogenicity along with pharmacodynamic and target engagement were observed, and anti-Aβ antibody titers were not associated with any adverse findings. These results support progression to clinical trials using an optimized formulation of the ACI-24 vaccine among individuals with DS.

What this study adds

Evidence grade: High

This is a trial of 20 participants. This phase 1b trial in 16 adults with Down syndrome found the ACI-24 vaccine was safe and produced antibodies in some participants. Reported effect size: 83.3%; 85.6%; 33.3%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rafii, M. S., Sol, O., Mobley, W. C., Delpretti, S., Skotko, B. G., Burke, A. D., et al. (2022). Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. JAMA neurology. https://doi.org/10.1001/jamaneurol.2022.0983

Vancouver

Rafii MS, Sol O, Mobley WC, Delpretti S, Skotko BG, Burke AD, et al. Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. JAMA neurology. 2022. doi:10.1001/jamaneurol.2022.0983. PMID: 35532913.

BibTeX

@article{rafii2022-35532913,
  author  = {Rafii, M. S. and Sol, O. and Mobley, W. C. and Delpretti, S. and Skotko, B. G. and Burke, A. D. and Sabbagh, M. N. and Yuan, S. H. and others},
  title   = {{Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.0983},
  pmid    = {35532913},
  url     = {https://doi.org/10.1001/jamaneurol.2022.0983}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This phase 1b trial in 16 adults with Down syndrome found the ACI-24 vaccine was safe and produced antibodies in some participants. It is an early safety and immune response study and does not show that the vaccine treats, cures, or prevents Alzheimer's disease.

Study details

How this study scored 71/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 71 of 100.71 of 100 points earned29 not earned

Published in a leading specialty journal, and it is a randomized controlled trial.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 1 / 4 20 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 4 / 7 Cited 52 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.7 citations a year over 6 year(s) since 2022
Impact for its field and year 3 / 6 Cited 5.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 5 other studies in this library
Still being cited 2 / 4 Cited 43 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Howard Feldman: h-index 105 (OpenAlex, whole career)
Institution's track record 2 / 3 Massachusetts General Hospital: institution h-index 2,057 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35532913)
Free to read 0 / 2 Behind a paywall — scores zero
Total 71 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →